A redundant epistatic interaction between IRF5 and STAT4 of the type I interferon pathway in susceptibility to lupus and rheumatoid arthritis

Abstract

Objective

K. K. and S.-K. C. are co-first authors, and C. K. and S.-C. B. are co-senior authors.

Two transcription factors in the type I interferon pathway, IRF5 and STAT4, have been genetically associated with susceptibility to both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This study aimed to determine whether these two genes interact with each other to affect the disease susceptibilities.

Methods

The genetic interactions between IRF5 and STAT4 polymorphisms in SLE and RA susceptibility were examined using the epistasis options in PLINK software. This study analyzes the genetic data from 2558 unrelated Korean participants including 589 SLE patients, 987 RA patients, and 982 controls.

Results

All 12 polymorphisms were individually associated with SLE susceptibility (p = 2.49 × 10⁻⁸ to 0.00360). Among the three SLE-associated polymorphisms of IRF5, rs77571059, alternatively called CGGGG(3–4) indel, exhibited the lowest p value (4.60 × 10⁻⁵) and accounted for the observed associations of the other two single-nucleotide polymorphisms (SNPs). Among the nine SLE-associated SNPs of STAT4, rs16833215 exhibited the lowest p value (2.49 × 10⁻⁸) and accounted for all the other associations. These two polymorphisms, rs77571059 of IRF5 and rs16833215 of STAT4, interacted with each other for SLE susceptibility in a redundant manner (OR_interaction = 0.77, P_epistasis = 0.040). Furthermore, these two polymorphisms, which had been individually associated with RA susceptibility, also interacted for RA susceptibility in the same manner (OR_interaction = 0.75, P_epistasis = 0.014).

Conclusions

A redundant interaction between IRF5 and STAT4 polymorphisms was found in susceptibility to the type I interferon pathway-associated rheumatic autoimmune diseases, SLE and RA, calling for further studies on confirmation of these findings.

Keywords

Genetic polymorphism epistatic interaction systemic lupus erythematosus rheumatoid arthritis type I interferon

Get full access to this article

View all access options for this article.

References

Higgs

Liu

White

. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029–2036.

Wang

Sandling

Hagberg

. Genome-wide profiling of target genes for the systemic lupus erythematosus-associated transcription factors IRF5 and STAT4. Ann Rheum Dis 2013; 72: 96–103.

Kariuki

Kirou

MacDermott

Barillas-Arias

Crow

Niewold

. Cutting edge: Autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009; 182: 34–38.

Takaoka

Yanai

Kondo

. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434: 243–249.

Barnes

Moore

Pitha

. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276: 23382–23390.

Marshak-Rothstein

. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823–835.

Tyler

Persky

Matthews

Chan

Farrar

. Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain. Mol Immunol 2007; 44: 1864–1872.

Graham

Kozyrev

Baechler

. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550–555.

Dieguez-Gonzalez

Calaza

Perez-Pampin

. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 1264–1274.

10.

Remmers

Plenge

Lee

. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977–986.

11.

Niewold

Kelly

Flesch

Espinoza

Harley

Crow

. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58: 2481–2487.

12.

Niewold

Kelly

Kariuki

. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012; 71: 463–468.

13.

Sigurdsson

Nordmark

Garnier

. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008; 17: 2868–2876.

14.

Shin

Kim

Choi

Lee

Bae

. Different genetic effects of interferon regulatory factor 5 (IRF5) polymorphisms on systemic lupus erythematosus in a Korean population. J Rheumatol 2008; 35: 2148–2151.

15.

Namjou

Sestak

Armstrong

. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum 2009; 60: 1085–1095.

16.

Kim

Park

Kim

. Putative role of functional interferon regulatory factor 5 (IRF5) polymorphism in rheumatoid arthritis in a Korean population. J Rheumatol 2008; 35: 2106–2118.

17.

Lee

Remmers

Kastner

Bae

Gregersen

. Association of STAT4 with rheumatoid arthritis in the Korean population. Mol Med 2007; 13: 455–460.

18.

Cordell

. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392–404.

19.

Yang

Khoury

Sun

Flanders

. Case-only design to measure gene-gene interaction. Epidemiology 1999; 10: 167–170.

20.

Lanktree

Hegele

. Gene-gene and gene-environment interactions: New insights into the prevention, detection and management of coronary artery disease. Genome Med 2009; 1: 28–28.

21.

Abelson

Delgado-Vega

Kozyrev

. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009; 68: 1746–1753.